Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed details new-hire equity inducement grants with defined vesting schedules and option terms under its 2025 Inducement Plan.
Rhea-AI Summary
Insmed (INSM) granted equity inducement awards to 128 new employees under its 2025 Inducement Plan, designed to comply with Nasdaq Listing Rule 5635(c)(4).
Effective August 31, 2026, the employees received a total of 115,320 restricted stock units and options to purchase an aggregate 5,560 shares of Insmed common stock at an exercise price of $121.82 per share, equal to the closing trading price on the grant date. The restricted stock units vest over four years in equal 25% annual installments, starting on the first anniversary of the first day of the month following the grant date, subject to continued service.
The stock options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first such anniversary and 12.5% vesting every six months thereafter through the fourth anniversary, also contingent on continued employment.
Positive
- None.
Negative
- None.
News Explained
For existing common holders, the awards create a potential future increase in shares outstanding: 115,320 restricted stock units can deliver shares as employees remain in service, while options for 5,560 shares require exercise; the release reports grants, not completed share issuance.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Sep 03 | respiratory data presentation | Neutral | +0.0% | Planned presentation of five respiratory portfolio abstracts at ERS Congress 2026 |
| Aug 26 | investor conference presentations | Neutral | +0.4% | Management scheduled presentations at two September healthcare investor conferences |
| Aug 24 | Japan regulatory approval | Positive | -1.4% | Japan approved BRINSUPRI for adults and pediatric patients with NCFB |
| Aug 06 | second-quarter earnings | Positive | +33.9% | Revenue growth and raised BRINSUPRI guidance drove the quarterly update |
| Jul 23 | earnings call scheduling | Neutral | +0.7% | Company scheduled its second-quarter financial results release and conference call |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Insmed's recent positive announcements generally coincided with positive price reactions, although the Japan approval announcement was followed by a negative reaction.
Key Terms
inducement awards regulatory
restricted stock units financial
vesting schedule financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
In connection with the commencement of their employment, on August 31, 2026, the employees received 115,320 restricted stock units and options to purchase an aggregate 5,560 shares of Insmed common stock at an exercise price of
The restricted stock units have a four-year vesting schedule, with
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines — including two approved therapies to treat chronic, debilitating lung diseases — as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. The Company's research engine is advancing a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue, in the pursuit of future pipeline candidates.
Headquartered in Bridgewater,
Contact:
Investors:
Sara Bonstein
Chief Financial Officer
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302869247.html
SOURCE Insmed Incorporated
FAQ
What inducement equity grants did Insmed (INSM) announce for new employees?
Insmed announced equity inducement grants for 128 new employees under its 2025 Inducement Plan. The grants include 115,320 restricted stock units and options to purchase an aggregate 5,560 shares of Insmed common stock, issued as a material inducement to join the company.
What is the exercise price and term of the new Insmed (INSM) stock options?
The inducement stock options have an exercise price of $121.82 per share, which matches the closing trading price on the grant date of August 31, 2026. These options carry a 10-year term, during which they may be exercised subject to vesting and continued employment.
How do the restricted stock units granted by Insmed (INSM) vest for new hires?
The 115,320 restricted stock units granted to new Insmed employees vest over four years. 25% of the shares underlying each RSU grant vest on each anniversary of the first day of the month immediately following the grant date, subject to the employee’s continued service.
What is the vesting schedule for the new Insmed (INSM) stock options?
The new stock options vest over four years. 25% of the shares subject to each option vest on the first anniversary of the first day of the month following the grant date, and 12.5% vest every six months thereafter through the fourth anniversary, contingent on continued employment.
Why were the Insmed (INSM) inducement grants made under Nasdaq Listing Rule 5635(c)(4)?
The grants were issued under the 2025 Inducement Plan, which is intended to satisfy Nasdaq Listing Rule 5635(c)(4) requirements. Insmed states that the awards were a material inducement to each employee’s entry into employment with the company, allowing equity grants without prior shareholder approval.